Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Spruce Biosciences, Inc.NASDAQ: SPRB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $12.27M (cash outflow) fell 12.6% year over year, ahead of the -32.9% change in trailing-twelve-month net income. Sequentially, it fell 16.3% from the prior quarter. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$24.52M (-37.1%) for the fiscal year ending Dec 2026, a slowdown from the -26.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$12.27M-16.3% QoQ
- Last fiscal yearDec 2025
- -$38.97M-26.5% YoY
- LTMMar 2026
- -$37.19M-32.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.6% | +581.0% | +593.6 pp |
| 1 year | -26.5% | -37.1% | -10.5 pp |
| 3-year CAGR | -5.5% | -47.0% | -41.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (38.97M) USD
- Year-over-year change
- +26.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.97M) | +26.5% |
| FY2024 | 2024-12-31 | (53.04M) | -10.7% |
| FY2023 | 2023-12-31 | (47.92M) | -3.8% |
| FY2022 | 2022-12-31 | (46.18M) | -9.2% |
| FY2021 | 2021-12-31 | (42.29M) | — |
Net Income vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 net income of $37.19M is the 3rd largest of the 9 companies compared; the peer median is $22.03M.
- Its year-over-year change of -32.9% is the 6th highest of 9, against a peer median of +7.2%.
- Over three fiscal years its annual growth of -5.5% compares with a peer median of -6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding SPRB) | $22.03M | +7.2% | -6.1% | 532.1% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.96M | 3.63M | 4.62M | 5.35M | 2.57M |
| Change in Working Capital | 1.96M | 1.13M | 10.36M | (8.57M) | (724K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (805K) | (1.4M) | 1.91M | (2.04M) | (352K) |
| Other Working Capital | 2.76M | 2.53M | 8.45M | (6.53M) | (372K) |
| Other Non-Cash Items | 434K | (340K) | (404K) | 249K | 3.77M |
| Operating Cash Flow | (35.88M) | (41.68M) | (33.28M) | (55.96M) | (33.33M) |
| Capital Expenditures | (93K) | (8K) | (7K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (79.08M) | (36.8M) | (11.88M) | 0 | 0 |
| Sales of Investments | 0 | 60.5M | 67.67M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (79.17M) | 23.69M | 55.78M | 0 | 0 |
| Debt Repayment | 220K | 0 | (1.62M) | (1.62M) | (2.06M) |
| Common Stock Issued | 0 | (201K) | 53.62M | 246K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 423K | (40K) | (2.85M) | (246K) | (4.53M) |
| Financing Cash Flow | 643K | (241K) | 49.14M | (1.62M) | 43.48M |
| Effect of Forex Changes | 0 | 187K | 0 | 0 | 0 |
| Net Change in Cash | (114.4M) | (18.05M) | 71.64M | (57.59M) | 10.15M |
| Free Cash Flow | (35.97M) | (41.69M) | (33.28M) | (55.96M) | (33.33M) |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.